

PRODUCT MONOGRAPH  
INCLUDING PATIENT MEDICATION INFORMATION

<sup>Pr</sup>**Spevigo**<sup>®</sup>

Spesolimab injection

Solution for subcutaneous injection

150 mg/1 mL (150 mg/mL)

Spesolimab for injection

Concentrate for solution for intravenous infusion

450 mg/7.5 mL (60 mg/mL)

Interleukin-36 Inhibitor

ATC code: L04AC22

Boehringer Ingelheim (Canada) Ltd.  
5180 South Service Road  
Burlington, Ontario  
L7L 5H4  
[www.boehringer-ingelheim.ca](http://www.boehringer-ingelheim.ca)

Date of Initial Authorization:  
March 22, 2023

Date of Revision:  
July 31, 2024

Submission Control Number: 278317

BICL #0174-02

Spevigo<sup>®</sup> is a registered trademark of Boehringer Ingelheim International GmbH, used under license.

**RECENT MAJOR LABEL CHANGES**

1 INDICATIONS	07, 2024
1 INDICATIONS, 1.1 pediatrics	07, 2024
4 DOSAGE AND ADMINISTRATION	07, 2024
4 DOSAGE AND ADMINISTRATION, 4.1 Dosing Considerations	07, 2024
4 DOSAGE AND ADMINISTRATION, 4.2 Recommended Dose and Dosage Adjustments	07, 2024
4 DOSAGE AND ADMINISTRATION, 4.4 Administration	07, 2024
4 DOSAGE AND ADMINISTRATION, 4.5 Missed Dose	07,2024
7 WARNINGS AND PRECAUTIONS	07, 2024
7 WARNINGS AND PRECAUTIONS, 7.1.3 Pediatrics	07, 2024

**TABLE OF CONTENTS**

Sections or subsections that are not applicable at the time of authorization are not listed.

**RECENT MAJOR LABEL CHANGES ..... 2**

**TABLE OF CONTENTS ..... 2**

**1 INDICATIONS..... 4**

    1.1 Pediatrics (<18 years of age).....**Error! Bookmark not defined.**

    1.2 Geriatrics (≥65 years of age).....4

**2 CONTRAINDICATIONS ..... 4**

**4 DOSAGE AND ADMINISTRATION ..... 4**

    4.1 Dosing Considerations .....4

    4.2 Recommended Dose and Dosage Adjustment .....4

    4.3 Reconstitution .....6

    4.4 Administration.....6

**5 OVERDOSAGE..... 7**

**6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING ..... 7**

**7 WARNINGS AND PRECAUTIONS ..... 8**

    7.1 Special Populations.....10

        7.1.1 Pregnant Women .....10

7.1.2	Breast-feeding .....	10
7.1.3	Pediatrics (<18 years of age).....	10
7.1.4	Geriatrics (≥65 years of age).....	10
<b>8</b>	<b>ADVERSE REACTIONS .....</b>	<b>11</b>
8.1	Adverse Reaction Overview.....	11
8.2	Clinical Trial Adverse Reactions .....	11
<b>9</b>	<b>DRUG INTERACTIONS .....</b>	<b>14</b>
9.2	Drug Interactions Overview.....	14
9.4	Drug-Drug Interactions.....	14
9.5	Drug-Food Interactions.....	14
9.6	Drug-Herb Interactions.....	14
9.7	Drug-Laboratory Test Interactions.....	14
<b>10</b>	<b>CLINICAL PHARMACOLOGY .....</b>	<b>14</b>
10.1	Mechanism of Action.....	14
10.2	Pharmacodynamics .....	14
10.3	Pharmacokinetics .....	14
<b>11</b>	<b>STORAGE, STABILITY AND DISPOSAL .....</b>	<b>16</b>
<b>12</b>	<b>SPECIAL HANDLING INSTRUCTIONS.....</b>	<b>17</b>
<b>13</b>	<b>PHARMACEUTICAL INFORMATION.....</b>	<b>18</b>
<b>14</b>	<b>CLINICAL TRIALS .....</b>	<b>18</b>
14.1	Clinical Trials by Indication .....	18
14.3	Immunogenicity.....	22
<b>15</b>	<b>MICROBIOLOGY .....</b>	<b>23</b>
<b>16</b>	<b>NON-CLINICAL TOXICOLOGY .....</b>	<b>23</b>
	<b>PATIENT MEDICATION INFORMATION.....</b>	<b>26</b>

## **PART I: HEALTH PROFESSIONAL INFORMATION**

### **1 INDICATIONS**

Spevigo (spesolimab injection/spesolimab for injection) is indicated for the treatment of generalized pustular psoriasis (GPP) in adults and pediatric patients 12 years of age and older and weighing at least 40 kg.

#### **1.1 Pediatrics (<18 years of age)**

The safety and efficacy of Spevigo have been established in pediatric patients with GPP aged 12 years and older (see section Clinical Trials).

The safety and efficacy of Spevigo in children below the age of 12 years have not been established. No data are available in this population.

#### **1.2 Geriatrics (≥65 years of age)**

No dose adjustment is required. There is limited information in patients 65 years and older.

### **2 CONTRAINDICATIONS**

Spevigo is contraindicated in patients with severe or life-threatening hypersensitivity to this drug or to any ingredient in the formulation, including any non-medicinal ingredient, or component of the container. For a complete listing, see [6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING](#).

### **4 DOSAGE AND ADMINISTRATION**

#### **4.1 Dosing Considerations**

Treatment with Spevigo for intravenous infusion should be initiated by physicians experienced in the management of patients with inflammatory skin diseases.

Spevigo treatment can be initiated with the Spevigo pre-filled syringe as a subcutaneous injection to prevent GPP flares or with an intravenous dose of Spevigo to treat a GPP flare.

Spevigo solution for injection in pre-filled syringe is intended for subcutaneous use for GPP flare prevention only. Spevigo concentration for solution for infusion is intended for intravenous use for GPP flare treatment only.

#### **4.2 Recommended Dose and Dosage Adjustment**

##### **Recommended dose for GPP flare prevention**

The recommended dose of Spevigo for GPP flare prevention in adults and adolescents from 12

years of age is a subcutaneous loading dose of 600 mg (four 150 mg injections), followed by 300 mg (two 150 mg injections) administered subcutaneously every 4 weeks.

Spevigo has not been studied in patients weighing less than 40 kg or below the age of 12 years (see [10.3 Pharmacokinetics](#)).

#### GPP flare treatment during subcutaneous GPP prevention treatment

If a patient experiences a GPP flare while receiving subcutaneous Spevigo, the GPP flare should be treated with intravenous Spevigo (see [4.2 Recommended Dose and Dosage Adjustment](#)).

#### Initiating or reinitiating subcutaneous GPP prevention treatment after intravenous GPP flare treatment

Four weeks after treatment with intravenous Spevigo, subcutaneous Spevigo can be initiated or reinitiated at a dose of 300 mg (two 150 mg injections) administered every 4 weeks. A subcutaneous loading dose is not required.

#### Recommended dose for GPP flare treatment

The recommended dose of Spevigo solution for infusion to treat a GPP flare is a single dose of 900 mg (two 450 mg/7.5 mL vials) administered as an intravenous infusion. If flare symptoms persist, an additional 900 mg dose (two 450 mg/7.5 mL vials) may be administered 1 week after the initial dose.

#### **Pediatrics (<18 years of age)**

The safety and efficacy of Spevigo have been established in adolescents with GPP aged 12 years and older (see 14 CLINICAL TRIALS).

The safety and efficacy of Spevigo in pediatric patients below the age of 12 have not been established. No data are available in this population.

#### **Geriatrics (≥65 years of age)**

No dose adjustment is required. There is limited information in patients aged 65 years and older.

#### **Renal or Hepatic Impairment**

Spevigo has not been formally studied in these patient populations. These conditions are generally not expected to have any clinically relevant impact on the pharmacokinetics of monoclonal antibodies and no dose adjustments are considered necessary.

### 4.3 Reconstitution

#### Parenteral Products:

##### Instructions for Dilution

Spevigo must be diluted before use.

The vial should be visually inspected before use. Spevigo is a colourless to slightly brownish-yellow, clear to slightly opalescent solution. If the solution is cloudy, discoloured, or contains large or coloured particulates, the vial should be discarded.

##### Preparation

- Use aseptic technique to prepare the solution for infusion.
- Draw and discard 15 mL from a 100 mL container of sterile 0.9% sodium chloride solution.
- Slowly replace with 15 mL of Spevigo (two vials of 450 mg/7.5 mL).
- Mix gently before use.
- The diluted Spevigo solution for infusion should be used immediately.

Spevigo is for single-use only and does not contain preservatives.

### 4.4 Administration

#### **Subcutaneous Injection Use (GPP Flare Prevention)**

The injection should be administered subcutaneously in the upper thighs or abdomen. Spevigo pre-filled syringe should not be injected into areas where the skin is tender, bruised, erythematous, indurated, or scarred.

If a 600 mg subcutaneous loading dose of Spevigo is needed (see [4.2 Recommended Dose and Dosage Adjustment](#)), the loading dose should be administered by a healthcare professional. A different injection site should be chosen for each injection, at least 2 cm away from the other injection sites.

For the subsequent subcutaneous 300 mg doses of Spevigo, if the healthcare professional determines that it is appropriate, patients may self-inject or caregivers may administer the Spevigo pre-filled syringe after proper training in subcutaneous injection technique.

For a complete 300 mg dose, two 150 mg/mL pre-filled syringes are required to be injected, one right after the other. A different injection site should be chosen for each of the two injections, at least 2 cm away from the other injection site.

#### **Intravenous Infusion Use (GPP Flare Treatment)**

- Do not mix Spevigo with other medicinal products.
- Administer Spevigo as a continuous intravenous infusion through an intravenous line containing a sterile, non-pyrogenic, low protein binding in-line filter (pore size of 0.2

micron) over 90 minutes.

- If the infusion is slowed or temporarily stopped, the total infusion time (including stop time) should not exceed 180 minutes (see [7 WARNINGS AND PRECAUTIONS](#)).
- A pre-existing intravenous line may be used for administration of Spevigo. The line must be flushed with sterile 0.9% sodium chloride solution prior to and at the end of infusion. No other infusion should be administered in parallel via the same intravenous access.
- No incompatibilities have been observed between Spevigo and infusion sets composed of polyvinylchloride (PVC), polyethylene (PE), polypropylene (PP), polybutadiene and polyurethane (PUR), and in-line filter membranes composed of polyethersulfone (PES, neutral and positively charged) and positively charged polyamide (PA).

#### 4.5 Missed Dose

##### **GPP flare prevention with Spevigo Subcutaneous Injection**

If a dose is missed, the dose should be administered as soon as possible. Thereafter, dosing should be resumed at the regular scheduled time.

#### 5 OVERDOSAGE

There is no clinical experience with overdoses of Spevigo.

The highest dose of Spevigo administered in GPP clinical trials was 900 mg intravenously or 600 mg subcutaneously. Adverse events observed in subjects receiving single or repeated doses up to 1200 mg in other clinical trials were consistent with the known safety profile of Spevigo.

In the event of overdose, it is recommended that the patient be monitored for any signs or symptoms of adverse reactions and symptomatic treatment be instituted as appropriate.

For management of a suspected drug overdose, contact your regional poison control centre.

#### 6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING

**Table 1 - Dosage Forms, Strengths, Composition and Packaging**

Route of Administration	Dosage Form / Strength / Composition	Non-medicinal Ingredients
Subcutaneous	Solution for injection 150 mg/mL	Arginine hydrochloride, glacial acetic acid, polysorbate 20, sodium acetate trihydrate, sucrose, water for injection
Intravenous infusion	Concentrate for Solution for Infusion 450 mg/7.5 mL (60 mg/mL)	Arginine hydrochloride, glacial acetic acid, polysorbate 20, sodium acetate trihydrate, sucrose, water for injection

### **Subcutaneous**

Spevigo is supplied in 1 mL pre-filled glass syringe with a needle safety device containing 150 mg/mL. Each pack has two syringes.

### **Intravenous Infusion**

Spevigo is supplied in a 10 mL clear glass vial with a coated rubber stopper containing 7.5 mL concentrate. Each pack has two vials.

The vial stopper is not manufactured with natural rubber latex.

### **Excipients**

This medicinal product contains less than 1 mmol sodium (23 mg), essentially 'sodium free'.

## **7 WARNINGS AND PRECAUTIONS**

### **General**

Limited safety data are available for re-treatment with spesolimab for a subsequent new flare.

### **Traceability**

In order to improve traceability of biological medicinal products, the trade name and the batch number of the administered product should be clearly recorded in the patient file.

### **Infections**

Spevigo may increase the risk of infections. Higher rates of infections such as urinary tract infections and upper respiratory infections were observed in patients receiving Spevigo compared with placebo (see [8 ADVERSE REACTIONS](#)).

In patients with a chronic infection or a history of recurrent infection, the potential risks and expected clinical benefits of treatment should be considered prior to prescribing Spevigo. Treatment with Spevigo should not be initiated in patients with any clinically important active infection until the infection resolves or is adequately treated. Patients should be instructed to seek medical advice if signs or symptoms of clinically important infection occur during or after treatment with Spevigo.

### **Spevigo Subcutaneous Injection**

If a patient is on treatment with Spevigo subcutaneous injection for GPP flare prevention, and develops a clinically important active infection, treatment with Spevigo should be stopped. Re-initiation can be considered once the infection resolves or is adequately treated.

### **Pre-treatment evaluation for tuberculosis**

Patients should be evaluated for tuberculosis (TB) infection prior to initiating treatment with



Spevigo. Spevigo should not be administered to patients with active TB infection.

Anti-TB therapy should be considered prior to initiating Spevigo in patients with latent TB or a history of TB in whom an adequate course of treatment cannot be confirmed. During and after Spevigo treatment, patients should be monitored for signs and symptoms of active TB.

#### Hypersensitivity and infusion-related reactions

Hypersensitivity and infusion-related reactions may occur with monoclonal antibodies such as Spevigo. Hypersensitivity may include immediate reactions such as anaphylaxis and delayed reactions such as drug reaction with eosinophilia and systemic symptoms (DRESS).

If a patient develops signs of anaphylaxis or other serious hypersensitivity, Spevigo should be discontinued immediately, and appropriate treatment should be initiated (see [2 CONTRAINDICATIONS](#)).

#### **Spevigo Subcutaneous Injection**

Prior to initiating Spevigo for GPP flare prevention, completion of all appropriate immunizations should be considered according to current immunization guidelines.

#### **Spevigo Intravenous Infusion**

If a patient develops mild or moderate hypersensitivity during an intravenous infusion or other infusion-related reactions, Spevigo should be stopped and appropriate medical therapy should be considered (e.g., systemic antihistamines and/or corticosteroids). Upon resolution of the reaction, the infusion may be restarted at a slower infusion rate with gradual increase to complete the infusion (see [4 DOSAGE AND ADMINISTRATION](#)).

#### Immunizations

No specific studies have been conducted in patients who have recently received live viral or live bacterial vaccines. Live vaccines should not be given concurrently with Spevigo. The interval between live vaccinations and initiation of Spevigo therapy should be at least 4 weeks. Live vaccines should not be administered during and for at least 16 weeks after treatment with Spevigo.

#### **Driving and Operating Machinery**

Spevigo has no or negligible influence on the ability to drive and use machines.

#### **Neurologic**

##### Peripheral neuropathy

The potential for peripheral neuropathy with Spevigo is unknown. Cases of peripheral

neuropathy have been reported in clinical trials with spesolimab. Physicians should be vigilant for symptoms potentially indicative of new-onset peripheral neuropathy.

## **Reproductive Health: Female and Male Potential**

- **Fertility**

There are no data available on the effect of Spevigo on human fertility. No specific non-clinical animal study on fertility has been conducted with spesolimab (see [16 NON-CLINICAL TOXICOLOGY](#)).

### **7.1 Special Populations**

#### **7.1.1 Pregnant Women**

There are limited data from the use of Spevigo in pregnant women. Non-clinical animal reproductive and developmental toxicology studies were not conducted with spesolimab due to lack of pharmacologic activity in non-human species (see [16 NON-CLINICAL TOXICOLOGY](#)). Human IgG are known to cross the human placental barrier. As a precautionary measure, it is recommended to avoid the use of Spevigo in pregnancy.

#### **7.1.2 Breast-feeding**

It is unknown whether Spevigo is excreted in human milk. There are no data on the effects on the breastfed infant, or the effects on milk production. Spesolimab is a monoclonal antibody and is expected to be present in human milk. A risk to newborns/infants cannot be excluded.

#### **7.1.3 Pediatrics (<18 years of age)**

The safety and efficacy of Spevigo have been established in adolescents with GPP aged 12 years and older. Use of Spevigo for this indication is supported by data from 8 adolescent patients aged 14 to 17 years included in EFFISAYIL-2, evidence from adequate and well controlled studies of Spevigo in adults with GPP, and pharmacokinetic analyses showing similar drug exposure levels in adults and pediatric subjects 12 years of age and older (see [8.2 Clinical Trial Adverse Reactions](#), [10.3 Pharmacokinetics](#) and [14 CLINICAL TRIALS](#)).

The safety and efficacy of Spevigo in pediatric patients younger than 12 years have not been established. No data are available in this population.

#### **7.1.4 Geriatrics (≥65 years of age)**

No dose adjustment is required. There is limited information in patients aged 65 years and older.

## 8 ADVERSE REACTIONS

### 8.1 Adverse Reaction Overview

Spevigo has been studied in clinical trials including 183 patients with GPP. The safety data provided in the following are based on two randomized, double-blind, placebo-controlled trials comparing treatment with Spevigo to placebo (EFFISAYIL-1 and EFFISAYIL-2).

The most frequent adverse reactions associated with Spevigo were infections. During the 1-week placebo-controlled period in EFFISAYIL-1, infections were reported in 17.1% of patients treated with Spevigo compared with 5.6% of patients treated with placebo. In EFFISAYIL-1, serious infection (urinary tract infection) was reported in 1 patient (2.9%) in the Spevigo group and no patients in the placebo group. During the placebo-controlled period of up to 48 weeks in EFFISAYIL-2, infections were reported in 33.3% of patients treated with Spevigo and 33.3% of patients treated with placebo. In EFFISAYIL-2, serious infections were reported in 3 patients (3.2%) in the Spevigo group and no patients in the placebo group. Infections observed in clinical trials with spesolimab were generally mild to moderate with no distinct pattern regarding pathogen or type of infection.

In EFFISAYIL-1, local tolerability was assessed after the Day 1 and the Day 8 infusions, based on 6 symptoms (swelling, induration, heat, redness, pain, other) and 3 grades of intensity (mild, moderate, severe). In the placebo group, 1 patient (5.6%) had symptoms (heat of moderate intensity) on Day 1 and no patient had symptoms on Day 8. In the Spevigo group, 6 patients (17.1%) had mild to moderate symptoms on Day 1 and no patient had symptoms on Day 8. No severe symptoms were reported in any treatment group.

### 8.2 Clinical Trial Adverse Reactions

Clinical trials are conducted under very specific conditions. The adverse reaction rates observed in the clinical trials therefore, may not reflect the rates observed in practice and should not be compared to the rates in the clinical trials of another drug. Adverse reaction information from clinical trials may be useful in identifying and approximating rates of adverse drug reactions in real-world use.

Spevigo was studied in a randomized, double-blind, placebo-controlled trial (EFFISAYIL-1) comparing a single intravenous 900 mg dose of Spevigo (n=35) with placebo (n=18) in patients with GPP experiencing an acute flare [see [14 CLINICAL TRIALS](#)].

Table 2 summarizes the adverse reactions that occurred at a rate of at least 1% and at a higher rate in the Spevigo group than in the placebo group through Week 1.

**Table 2 – Selected Adverse Reactions Occurring in  $\geq 1\%$  of the Spevigo Group and More Frequently than in the Placebo Group through Week 1**

<b>Adverse Reaction</b>	<b>Spevigo N=35 n (%)</b>	<b>Placebo N=18 n (%)</b>
Asthenia and fatigue	3 (9)	1(6)
Headache	3 (9)	1 (6)
Pruritus and prurigo	2 (6)	0
Infusion site hematoma and bruising	2 (6)	0
Urinary tract infection	2 (6)	0
Bacteremia	1 (3)	0
Bacteriuria	1 (3)	0
Cellulitis	1 (3)	0
Herpes dermatitis and oral herpes	1 (3)	0
Upper respiratory tract infection	1 (3)	0
Dyspnea	1 (3)	0
Eye edema	1 (3)	0
Urticaria	1 (3)	0

Subjects in either treatment group who continued to experience flare symptoms at Week 1 were eligible to receive a single open-label intravenous dose of 900 mg of Spevigo (second dose and first dose for subjects in the Spevigo and placebo groups, respectively). At Week 1, 12 (34%) subjects and 15 subjects (83%) in the Spevigo and placebo groups, respectively, received open-label Spevigo. After Week 1 to Week 12, subjects in either treatment group whose GPP flare reoccurred after achieving a clinical response were eligible to receive a single open-label rescue intravenous dose of 900 mg of Spevigo, with a maximum of 3 total doses of Spevigo throughout the study. Six subjects received a single open-label rescue dose of Spevigo. Thirty-six subjects received 1 dose of Spevigo, 13 subjects received 2 doses of Spevigo, and 2 subjects received 3 doses of Spevigo throughout the study.

In study EFFISAYIL-1, additional adverse reactions that occurred through Week 12 in subjects treated with 1 single dose of randomized Spevigo were mild to moderate infections: device-related infection (3%), subcutaneous abscess (3%), furuncle (3%), and influenza (3%).

Additional adverse reactions that occurred through Week 17 in subjects treated with a single dose of open-label Spevigo at Week 1 (second dose and first dose for subjects in the Spevigo and placebo groups, respectively) were mild to moderate infections: otitis externa (7%), vulvovaginal candidiasis (4%), vulvovaginal mycotic infection (4%), and latent tuberculosis (4%), diarrhea (11%), and gastritis (4%). No new adverse reactions were identified for up to 16 weeks in subjects treated with a single dose of open-label rescue Spevigo from Week 1 to Week 12 (range 1-3 total doses).

## EFFISAYIL-2

Subcutaneous treatment with Spevigo was studied in EFFISAYIL-2, a randomized, placebo-controlled, double-blind, parallel group trial evaluating three doses of Spevigo (n=93) or placebo (n=30) in patients with generalized pustular psoriasis. Patients were randomized (1:1:1:1) to receive a 600 mg loading dose (LD) of Spevigo followed by 300 mg every 4 weeks, one of two other dosages of Spevigo, or placebo for up to 48 weeks. (see [4.2 Recommended Dose and Dosage Adjustment; 14.1 Clinical Trials by Indication](#)).

Patients ranged in age from 14 to 75 years (mean age was 40 years); 64% of patients were Asian and 36% were Caucasian; 62% of patients were female.

Table 3 describes patients who received any of the 3 doses of Spevigo and experienced adverse reactions that occurred at a rate of at least 3% and at a higher rate in the Spevigo group than in the placebo group through Week 48.

**Table 3 – Adverse Reactions Occurring in ≥3% of the Spevigo Group and More Frequently than in Placebo Group through Week 48 (EFFISAYIL-2).**

Adverse Reaction	Spevigo N=93 n (%)	Placebo N=30 n (%)
Injection site reactions*	17 (18)	2 (7)
Urinary tract infection	5 (5)	0 (0)
Pruritus	4 (4)	0 (0)

\*Includes erythema, pain, swelling, induration, urticaria, and warmth at the injection site. Injection site reactions observed in EFFISAYIL-2 were typically mild to moderate in severity.

### **8.2.1 Clinical Trial Adverse Reactions - Pediatrics**

The available data with Spevigo in pediatric subjects are limited. No new safety concerns were identified based on the limited number of treated adolescent subjects.

## 9 DRUG INTERACTIONS

### 9.2 Drug Interactions Overview

No interaction studies have been performed. In GPP patients, spesolimab is not expected to cause cytokine-mediated CYP interactions as a perpetrator.

Live vaccines should not be given concurrently with Spevigo (see [7 WARNINGS AND PRECAUTIONS](#)).

### 9.4 Drug-Drug Interactions

No formal drug interactions studies have been conducted with Spevigo.

### 9.5 Drug-Food Interactions

Interactions with food have not been established.

### 9.6 Drug-Herb Interactions

Interactions with herbal products have not been established.

### 9.7 Drug-Laboratory Test Interactions

Interactions with laboratory tests have not been established.

## 10 CLINICAL PHARMACOLOGY

### 10.1 Mechanism of Action

Spesolimab is a humanized antagonistic monoclonal immunoglobulin G1 (IgG1) antibody that blocks interleukin-36 (IL-36) signalling by binding to IL-36 receptor (IL-36R). Binding of spesolimab to IL-36R prevents the subsequent activation of IL-36R by its ligands (IL-36  $\alpha$ ,  $\beta$  and  $\gamma$ ) and downstream activation of pro-inflammatory and pro-fibrotic pathways.

There is evidence that suggests the link between IL36R signalling and skin inflammation but the precise mechanism of how the decrease in IL-36R signalling in the skin of GPP patients is linked to the treatment is not clear.

### 10.2 Pharmacodynamics

The pharmacodynamic effect of spesolimab in treatment of GPP has not been fully characterized.

### 10.3 Pharmacokinetics

A population pharmacokinetic (PK) model was developed based on data collected from healthy subjects, patients with GPP and patients with other diseases. After a single intravenous dose of 900 mg spesolimab, the population PK model-estimated  $AUC^{0-\infty}$  (95% CI) and  $C_{max}$  (95% CI) in a typical anti-drug antibody (ADA)-negative patient with GPP were 4750 (4510, 4970) mcg·day/mL and 238 (218, 256) mcg/mL, respectively. After a 600 mg subcutaneous loading dose of spesolimab followed by 300 mg spesolimab subcutaneously every 4 weeks, the

geometric mean observed steady -state trough concentration ranged from 29.4 mcg/mL to 38.1 mcg/mL. Steady-state trough concentrations were reached after 4 weeks of dosing.

When administered intravenously, spesolimab AUC increased approximately dose-proportionally within the dose range of 0.3 to 20 mg/kg with clearance (CL) and terminal half-life independent of dose.

Following subcutaneous single dose administration, spesolimab exposure increased slightly more than dose-proportionally across the dose range of 150 mg to 600 mg due to slightly increased bioavailability at higher doses.

**Table 4 – Typical PK parameters of spesolimab following a single intravenous dose of 900 mg or at steady-state following subcutaneous administration of spesolimab in GPP patients<sup>1</sup>.**

Route of Administration	C <sub>max</sub> [mcg/mL]	AUC [mcg·day/mL]	T <sub>max</sub> [day]	C <sub>trough,ss</sub> [mcg/mL]	Vd [L]	T <sub>1/2</sub> [Day]	CL [L/day]
Intravenous <sup>2</sup>	238 (218,256)	4750 (4510, 4970)	--	--	6.39 (6.17, 6.70)	25.5 (24.4, 26.3)	0.184 (0.175, 0.194)
Subcutaneous <sup>3</sup>	--	--	5-7 <sup>4</sup>	29.4- 38.1 <sup>5</sup>			

<sup>1</sup>all PK parameters (95% CI, if applicable) were estimated using population PK for a typical ADA-negative GPP patient unless otherwise specified.

<sup>2</sup> after a single intravenous dose of 900 mg spesolimab

<sup>3</sup> after a 600 mg subcutaneous loading dose of spesolimab followed by 300 mg spesolimab subcutaneously every 4 weeks

<sup>4</sup> observed median T<sub>max</sub> in healthy volunteers

<sup>5</sup> observed geometric mean in EFFISAYIL-2

### Absorption:

After subcutaneous administration in the abdomen, absolute bioavailability was 65%, at the, 300 mg dose. Subcutaneous administration of 300 mg spesolimab into the thigh resulted in an approximately 40% increase in AUC<sub>t</sub> and a 56% increase in C<sub>max</sub> compared to administration into the abdomen based on limited data from healthy volunteers.

Following subcutaneous single dose administration of spesolimab in healthy volunteers, peak plasma concentrations were achieved between 5.5 to 7.0 days after dosing

### Distribution:

Based on the population PK analysis, the typical volume of distribution at steady state was 6.4 L.

**Metabolism:**

The metabolic pathway of spesolimab has not been characterized. As a humanized IgG1 monoclonal antibody, spesolimab is expected to be degraded into small peptides and amino acids via catabolic pathways in a manner similar to endogenous IgG.

**Elimination:**

At dose range 0.3-20 mg/kg, in a typical GPP patient weighing 70 kg without ADA formation, the population PK model predicted spesolimab CL (95% CI) was 0.184 (0.175, 0.194) L/day. The terminal-half-life was 25.5 (24.4, 26.3) days.

**Special Populations and Conditions**

**Pediatric population:** The pharmacokinetics of spesolimab in pediatric patients below the age of 12 years have not been studied.

The plasma pharmacokinetics of spesolimab observed in adolescents were consistent with that observed in adults. No difference in plasma exposure is expected between adolescents and adults other than due to body weight. Population pharmacokinetic simulations show overlapping exposure between these populations at steady state. In adults and adolescents, the simulated median  $C_{trough,ss}$  (95% PI) following the recommended subcutaneous dosing regimen was 31.8 mcg/mL (10.3, 84.9) and 43.2 mcg/mL (11.1, 101) respectively. Similarly, the simulated median  $C_{max,ss}$  (95% PI) was 58.8 mcg/mL (22.8, 132) and 77.2 mcg/mL (25.4, 160) in adults and adolescents respectively.

**Age, Gender and Race:** Based on population pharmacokinetic analyses, age, gender and race did not have an effect on the pharmacokinetics of spesolimab.

**Hepatic and renal insufficiency:** As a monoclonal antibody, spesolimab is not expected to undergo hepatic or renal elimination. No formal study of the effect of hepatic or renal impairment on the pharmacokinetics of spesolimab was conducted.

**Body weight:** Spesolimab concentrations were increased in subjects with lower body weight and decreased in subjects with higher body weight. The clinical impact of body weight on spesolimab plasma concentrations is not yet clear. The pharmacokinetics of spesolimab have not been studied in patients weighing less than 40 kg.

**11 STORAGE, STABILITY AND DISPOSAL****Spevigo Subcutaneous Injection***Pre-filled Syringes*

Store in a refrigerator at 2°C - 8°C in original carton to protect from light. Do not freeze.

Prior to use, Spevigo pre-filled syringe may be kept at temperatures up to 25 °C for up to 14



days, if stored in the original package, in order to protect from light. Spevigo pre-filled syringe must be discarded if it has been kept at temperatures up to 25 °C for more than 14 days.

Spevigo pre-filled syringe must not be used if frozen, even if it has been thawed.

### **Spevigo Intravenous Infusion**

#### *Single-dose vials*

Spevigo sterile concentrate is for single-use only and does not contain preservatives.

Store in a refrigerator at 2°C - 8°C in original carton to protect from light. Do not freeze.

Prior to use, the unopened vial may be stored at room temperature (15°C-30°C) for up to 24 hours in the original package to protect from light.

For storage conditions after dilution of the medicinal product, see [12 SPECIAL HANDLING INSTRUCTIONS](#).

## **12 SPECIAL HANDLING INSTRUCTIONS**

The diluted Spevigo solution for infusion should be used immediately. If not used immediately, the diluted drug product may be stored for up to 4 hours at 2-8°C. The diluted solution for infusion should be stored protected from light from the time of preparation to start of administration.

Any unused medicinal product or waste material should be disposed of in accordance with local requirements.

## PART II: SCIENTIFIC INFORMATION

### 13 PHARMACEUTICAL INFORMATION

#### Drug Substance

Proper name: Spesolimab

Chemical name: Not applicable. Spesolimab is an immunoglobulin.

Molecular mass: 146 kDA

Structural formula: Spesolimab is a humanized monoclonal IgG1 antibody (mAb) against human IL-36R. The spesolimab molecule is composed of two heterodimers. Each heterodimer is composed of a heavy chain (449 amino acids) and a light chain (215 amino acids). The four polypeptide chains of the antibody are linked together by disulfide bonds. Each heavy polypeptide chain contains one consensus sequence for N-linked glycosylation.

Physicochemical properties: spesolimab is a colourless to slightly brownish-yellow, clear to slightly opalescent solution.

### 14 CLINICAL TRIALS

#### 14.1 Clinical Trials by Indication

##### 14.1.1 Treatment of Flares in patients with generalized pustular psoriasis (EFFASAYIL-1)

**Table 5 - Summary of patient demographics for clinical trials in treatment of flares in patients with generalized pustular psoriasis**

Study #	Study design	Dosage, route of administration and duration	Study subjects (n)	Mean age (Range)	Sex
EFFISAYIL-1 (Study 1368-0013)	Randomized, double-blind, placebo-controlled, in adults with flares of GPP  Post week 1-week 12: open label	900 mg, intravenous infusion, single dose with optional second dose at day 8 (follow up to 12 weeks)	Spevigo:35 Placebo:18	43 years (21 to 69)	Male: 32% Female:68%

A randomized, double-blind, placebo-controlled study (EFFISAYIL-1) was conducted to evaluate the clinical efficacy and safety of Spevigo in adult patients with flares of Generalized Pustular Psoriasis (GPP), regardless of IL36RN mutation status. Patients were randomised if they had a flare of GPP of moderate-to-severe intensity, as defined by a Generalized Pustular Psoriasis Physician Global Assessment (GPPGA) total score (which ranges from 0 [clear] to 4 [severe]) of

at least 3 (moderate), presence of fresh pustules (new appearance or worsening of pustules), GPPGA pustulation sub score of at least 2 (mild), and at least 5% of body surface area (BSA) covered with erythema and the presence of pustules. Patients were required to discontinue systemic and topical therapy for GPP prior to receiving study drug.

The primary endpoint of the study was the proportion of patients with a GPPGA pustulation subscore of 0 (indicating no visible pustules) at Week 1. The key secondary endpoint of the study was the proportion of patients with a GPPGA total score of 0 or 1 (clear or almost clear skin) at Week 1. Additional secondary endpoint at Week 4 was the proportion of patients with a 75% reduction in the Psoriasis Area and Severity Index for Generalized Pustular Psoriasis (GPPASI 75).

A total of 53 patients were randomized to receive a single intravenous dose of 900 mg - Spevigo (n= 35) or placebo (n=18). Patients in either treatment arm who still experienced flare symptoms at Week 1 were eligible to receive a single intravenous dose of open-label 900 mg Spevigo, resulting in 12 patients (34%) in the Spevigo arm receiving a second dose of Spevigo and 15 patients (83%) in the placebo arm receiving one dose of Spevigo on Day 8. In addition, 6 patients (4 Spevigo arm; 2 placebo arm) received rescue treatment with a single 900 mg dose of intravenous Spevigo for reoccurrence of a flare after Week 1.

The study population consisted of 32% men and 68% women. The mean age was 43 (range: 21 to 69) years; 55% of patients were Asian and 45% were Caucasian. Most patients included in the study had a GPPGA pustulation sub score of 3 (43%) or 4 (36%), and patients had a GPPGA total score of 3 (81%) or 4 (19%). A total of 13 of 53 (24.5%) patients had been previously treated with biologic therapy for GPP.

### Study results

The study met the pre-specified objectives at Week 1 for both GPPGA pustulation sub score of 0 (indicating no visible pustules) and GPPGA total score of 0 or 1 (clear or almost clear skin). Results are shown in Table .

**Table 6 - GPPGA Pustulation Sub Score and GPPGA Total Score at Week 1 (EFFISAYIL-1)**

	Spevigo 900 mg IV	Placebo
Number of Patients analysed	35	18
Patients achieving a GPPGA pustulation sub score of 0, n (%)	19 (54.3)	1 (5.6)
Risk difference versus placebo, % (95% CI)	48.7 (21.5, 67.2)	
p-value*	0.0004	
Patients achieving a GPPGA total score of 0 or 1, n (%)	15 (42.9)	2 (11.1)

Risk difference versus placebo, % (95% CI)	31.7 (2.2, 52.7)
p-value*	0.0118

GPPGA = Generalized Pustular Psoriasis Physician Global Assessment; IV = intravenous

\*One-sided p-value

#### 14.1.2 Prevention of Flares in patients with generalized pustular psoriasis (EFFISAYIL-2)

**Table 7 - Summary of patient demographics for clinical trials in prevention of flares in patients with generalized pustular psoriasis**

Study #	Study design	Dosage, route of administration and duration	Study subjects (n)	Mean age (Range)	Sex
EFFISAYIL-2 (Study 1368-0027)	Randomized, double-blind, placebo-controlled, in adults and adolescents with a history of GPP	<ul style="list-style-type: none"> <li>• Spevigo 600 mg SC LD followed by 300 mg SC every 4 weeks</li> <li>• Spevigo 600 mg SC LD followed by 300 mg SC every 12 weeks</li> <li>• Spevigo 300 mg SC LD followed by 150 mg SC every 12 weeks</li> <li>• Placebo SC LD followed by 150 mg SC every 4 weeks</li> </ul> 44 weeks (last dose)	Total: 123	40 years (14 to 75)	Male: 38% Female: 62%
			30		
			31		
			31		
			31		

SC: subcutaneous; LD: loading dose

A randomized, double-blind, placebo-controlled phase II b study (EFFISAYIL-2) was conducted to evaluate the efficacy and safety of Spevigo for subcutaneous administration in adult and adolescent patients weighing at least 40 kg) with a history of at least two GPP flares of moderate-to-severe intensity in the past, regardless of IL36RN mutation status. Patients were randomized if they had a GPPGA total score of 0 or 1 at screening and randomization. Patients were required to discontinue systemic and topical therapy for GPP prior to or at randomization. These patients must have had a history of flaring while on concomitant treatment for GPP or a history of flaring upon dose reduction or discontinuation of these concomitant medications.

The primary endpoint of the study was the time to the first GPP flare up to Week 48 (defined by a GPPGA pustulation subscore of  $\geq 2$  and an increase in GPPGA total score by  $\geq 2$  from

baseline). The key secondary endpoint of the study was the occurrence of at least one GPP flare up to Week 48.

While 3 dosing regimens were studied in EFFISAYIL-2, the recommended dosing regimen for GPP flare prevention is a subcutaneous loading dose of 600 mg Spevigo followed by 300 mg subcutaneous treatment administered every 4 weeks (see [4 DOSAGE AND ADMINISTRATION](#)). The results summarized below are those for the recommended dosing regimen.

Patients who experienced a flare were eligible to receive up to two open-label, intravenous doses of 900 mg Spevigo (see [4 DOSAGE AND ADMINISTRATION](#)). Two (6.7%) patients in the Spevigo arm for the recommended dose and 15 (48.4%) patients in the placebo arm received intravenous flare treatment.

The study population consisted of 38% men and 62% women. The mean age was 40(range: 14 to 75) years with 8 (6.5%) adolescent patients (2 per treatment arm); 64% of patients were Asian and 36% were Caucasian. Patients included in the study had a GPPGA pustulation sub score of 1 (28.5%) or 0 (71.5%), and patients had a GPPGA total score of 1 (86%) or 0 (14%). At the time of randomization, 75% of patients were treated with systemic therapy for GPP, which was discontinued at the start of the randomized study treatment.

## Study results

The number of subjects who experienced at least one GPP flare and the time to first GPP flare are presented in Table 7 and Figure 1. The study met the pre-specified objective for time to the first GPP flare up to Week 48.

**Table 8 - Time to the first GPP flare and occurrence of at least one GPP flare up to Week 48 (EFFISAYIL- 2)**

	Spevigo	Placebo
Number of Patients analysed	30	31
Patients with GPP flares, n (%)*	3 (10.0)	16 (51.6)
Hazard ratio (HR)** for the time to the first flare vs placebo (95% CI)	0.16 (0.05,0.54)	
p-value***	0.0005	
Risk difference for GPP flare occurrence vs placebo, % (95% CI)	-39.0 (-62.1, -15.9)	
p-value****	0.0013	


\*The use of intravenous Spevigo treatment or investigator-prescribed standard of care to treat GPP worsening were considered as onset of GPP flare

\*\*Cox regression model stratified by the use of systemic GPP medications at randomisation

\*\*\*Log-rank test stratified by the use of systemic GPP medications at randomisation, one-sided p-value

\*\*\*\*Cochran-Mantel-Haenszel test after multiple imputation, stratified by the use of systemic GPP medications at randomization, one-sided p-value

**Figure 1 Time to the first GPP flare up to Week 48 (EFFISAYIL- 2)**



Patients at risk

Placebo	31	23	20	20	19	17	17	17	17	16	15	15	11
Spesolimab s.c. recommended dose	30	26	26	26	26	26	25	24	23	22	22	22	18

The results of the primary and key secondary endpoints were generally consistent across subgroups including sex, age, race, BMI, body weight, mutation status in IL36RN, concurrent plaque psoriasis, GPPGA total score at baseline, and irrespective of any systemic GPP treatment at randomization.

### 14.3 Immunogenicity

As with all therapeutic proteins, there is the potential for immunogenicity. The detection of antibody formation is highly dependent on the sensitivity and specificity of the assay.

In patients with GPP treated with spesolimab in EFFISAYIL-1 (study 1368-0013), anti-drug antibodies (ADA) formed with a median onset of 2.3 weeks. Following administration of IV spesolimab 900 mg, 24% (12 out of 50) of patients had a maximum ADA titer greater than 4000 and were neutralizing antibody (Nab)-positive by end of the trial (Weeks 12 to 17). In patients with GPP treated with spesolimab in EFFISAYIL- 2 (study 1368-0027), ADA formed with a median onset of 8 weeks. Following administration of a 600 mg subcutaneous loading dose of spesolimab followed by 300 mg spesolimab subcutaneously every 4 weeks for a total

duration of 48 weeks, 24% of patients had a maximum ADA titer greater than 4 000 and were Nab-positive.

Following intravenous spesolimab, females appeared to have higher immunogenicity response; the percentage of patients with ADA titer greater than 4000 was 30% in females, and 12% in males, respectively. Following subcutaneous spesolimab, the comparative data on immunogenicity response in males versus females were inconclusive.

In patients with ADA titers below 4000, no apparent impact on spesolimab pharmacokinetics was observed. Following intravenous spesolimab, in most patients with ADA titer values greater than 4000, plasma spesolimab concentrations were considerably lower. Following subcutaneous spesolimab, the mean plasma steady-state trough concentrations in ADA-positive patients with titers greater than 4 000 were approximately 77% to 107% of trough concentrations in patients who were ADA-negative or ADA-positive with titer values  $\leq$  4 000.

In the presence of ADA, efficacy was observed upon re-treatment of subsequent flares with intravenous spesolimab in an open label extension trial. After subcutaneous administration of spesolimab, there was no consistent impact of ADA presence on efficacy.

There was no consistent correlation between the presence of ADA to spesolimab and hypersensitivity reactions following intravenous or subcutaneous administration of spesolimab.

## 15 MICROBIOLOGY

No microbiological information is required for this drug product.

## 16 NON-CLINICAL TOXICOLOGY

Animal toxicology studies have not been conducted with spesolimab due to a lack of pharmacologic activity in non-human species. The repeat-dose, reproductive, and developmental toxicology studies were conducted in mice using a surrogate, mouse specific anti-IL36R monoclonal antibody (BI 674304).

### General Toxicology:

In the pivotal repeat-dose toxicology study, mice were administered BI 674304 by intravenous injection twice per week for 26 weeks at doses of 0 (vehicle), 10, or 50 mg/kg. Additional groups of mice administered vehicle or high-dose BI 674304 were observed for a 4-week recovery period following dosing. There were ten unscheduled deaths during the course of the study (3, 2 and 5 mice from the control, 10 and 50 mg/kg groups, respectively).

The cause of mortality/moribundity was determined in 3 of the 10 mice; 1) euthanasia due to an abrasion on the tail that led to ulceration and infection, which impaired dosing (50 mg/kg), 2) euthanasia due to systemic bacterial infection (50 mg/kg) and 3) malignant lymphoma, a

type of cancer that occurs naturally in this strain of mouse (10 mg/kg). These findings were considered incidental, however, a relationship of BI 674304 treatment to infection cannot be excluded.

The cause of mortality/moribundity in the other 7 animals could not be determined; these 7 mortalities were not considered related to the administration of BI 674304 as they occurred across all dose groups, including the control.

No adverse changes in body weight, food consumption or clinical observations were noted at this dose. No adverse effects on clinical pathology parameters including haematology, immunophenotyping, clinical chemistry and histopathology, including lymphoid tissues, have been observed.

### **Carcinogenicity:**

Carcinogenicity and mutagenicity studies have not been conducted with spesolimab or BI 674304.

### **Genotoxicity:**

Genotoxicity studies have not been conducted with spesolimab or BI 674304.

### **Reproductive and Developmental Toxicology:**

Pre-clinical studies conducted in mice using a surrogate antibody directed towards murine IL-36R do not indicate direct or indirect harmful effects with respect to pregnancy, embryonic/fetal development or fertility, at intravenous doses up to 50 mg/kg twice weekly. Serum concentrations of BI 674304 were low in the females of these studies. The reproductive and developmental data should be interpreted with caution.



**Table 9 - Reproductive Toxicology**

Study Type	Species	No. of animals/group	Doses (mg/kg/twice weekly IV)	Findings
Fertility and early embryonic development study	Mice	22m 22f	0, 10, 50 2-4 weeks prior to cohabitation, during cohabitation, and/or gestation	NOAEL = 50 mg/kg. BI 674304 was neither a teratogen nor embryotoxic. BI 674304 did not affect fertility of the adult mice nor the development of the pups exposed via the treated mother.
Embryo fetal development study	Mice	25f	0, 10, 50 GD 6, 9, 12, and 15	A higher number of resorptions was observed but was within the historical control range and therefore an effect of BI 674304 was considered to be equivocal.
Pre- and postnatal development study	Mice	22f	0, 10, 50 GD 6 to LD 18	NOAEL = 50 mg/kg. BI 674304 did not affect pregnancy or delivery; or morphological, functional and immunological developmental parameters of offspring.

GD, gestation day; LD, lactation day

**Juvenile Toxicity:**

Juvenile toxicity studies have not been conducted with spesolimab or BI 674304.

## PATIENT MEDICATION INFORMATION

### READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE

**PrSpevigo®**

#### **Spesolimab for Injection/Spesolimab Injection, for intravenous or subcutaneous use**

Read this carefully before you start taking **Spevigo** and each time you get a refill. This leaflet is a summary and will not tell you everything about this drug. Talk to your healthcare professional about your medical condition and treatment and ask if there is any new information about **Spevigo**.

#### **What is Spevigo used for?**

**Spevigo** is a prescription medicine used in adults and children who are 12 years of age and older to treat and prevent:

painful skin blisters (also called pustules) developing suddenly over large areas of your skin.

These episodes are also known as a flare, and are related to a rare, inflammatory, skin disease called generalized pustular psoriasis (GPP). **Spevigo** helps to clear your skin and reduces your symptoms such as burning, itching, pain, redness, and fatigue during a flare.

#### **How does Spevigo work?**

**Spevigo** contains the active substance spesolimab. Spesolimab is a monoclonal antibody belonging to a group of medicines called interleukin (IL) inhibitors. Monoclonal antibodies are proteins that recognize and bind specifically to certain proteins in the body. **Spevigo** works by blocking the activity of a protein called IL-36R, which can cause pustules, painful inflammation on the skin and fibrosis (scarring).

#### **What are the ingredients in Spevigo?**

Medicinal ingredient: spesolimab

Non-medicinal ingredients: arginine hydrochloride, glacial acetic acid, polysorbate 20, sodium acetate trihydrate, sucrose, water for injection.

#### **Spevigo comes in the following dosage forms:**

**Spevigo** is available as pre-filled syringes, 150 mg/syringe (150 mg/mL)  
Each pack has two pre-filled syringes.

**Spevigo** is available as single use vials, 450 mg/vial (60 mg/mL).  
Each pack has two vials.

The vial stopper does not contain natural rubber latex.

**Do not use Spevigo if:**

You are allergic to spesolimab or any of the other ingredients of this medicine. See **What are the ingredients in Spevigo?**

**To help avoid side effects and ensure proper use, talk to your healthcare professional before you take Spevigo. Talk about any health conditions or problems you may have, including if you:**

- have an infection that does not go away or that keeps coming back;
- have tuberculosis (TB) or have been in close contact with someone with TB;
- have recently received or are scheduled to receive an immunization (vaccine). You should not receive live vaccines for at least 16 weeks after treatment with **Spevigo**;
- are pregnant or plan to become pregnant. It is not known if **Spevigo** can harm your unborn baby;
- are breastfeeding or plan to breastfeed. It is not known if **Spevigo** passes into your breast milk;
- experience symptoms like new-onset weakness in your arms or legs or numbness (loss of sensation), tingling or burning sensation in any part of your body. These might be signs of peripheral neuropathy.

**Talk to your healthcare professional right away if you have any of the signs or symptoms of an allergic reaction, including:**

- difficulty breathing or swallowing;
- swelling of the face, lips, tongue or throat;
- severe itching of the skin, with a red rash or raised bumps that is different from your GPP symptoms;
- feel faint.

You can also have allergic reactions days or weeks after receiving **Spevigo**. Call your doctor immediately if you develop any widespread skin rash not previously experienced, fever, and/or facial swelling 2-8 weeks after receiving the medication.

**Tell your healthcare professional about all the medicines you take, including any drugs, vitamins, minerals, natural supplements, or alternative medicines.**

**How to take Spevigo:**

**When given under the skin (subcutaneously) for GPP flare prevention**

- **Read the Instructions for Use that comes with Spevigo for information on how to prepare and inject a dose of Spevigo and how to properly throw away (dispose of) used Spevigo prefilled syringes.**
- Your healthcare provider will tell you how often you should use **Spevigo**. Use **Spevigo** exactly as your healthcare provider tells you to use it.

- Do not try to inject **Spevigo** until you have been shown the right way to give the injections by your healthcare provider. If your healthcare provider decides that you or a caregiver may give your injections of **Spevigo** at home, you should receive training on the right way to prepare and inject **Spevigo**.
- If you miss a dose of **Spevigo**, inject your dose as soon as you remember. Then, take your next dose at your regular scheduled time. In case you are not sure when to inject **Spevigo**, call your healthcare provider.
- Subcutaneous injection of **Spevigo** should not be used for GPP flare treatment.

#### **When given in a vein (intravenously) for GPP flare treatment**

- Your healthcare provider will give you **Spevigo** through a needle placed in your vein (intravenous infusion) over 90 minutes.
- **Spevigo** is usually given one time. Your healthcare provider will decide if you should receive an additional treatment after 1 week.
- Intravenous infusion of **Spevigo** should not be used for GPP flare prevention.

#### **Usual dose:**

The usual dose for **GPP flare prevention** is a loading dose of 600 mg (4 x 150 mg/1mL syringes) followed by 300 mg (2 x 150 mg/1 mL syringes) administered subcutaneously 4 weeks later and every 4 weeks thereafter.

The usual dose for **GPP flare treatment** is a single dose of 900 mg (2 x 450 mg/7.5 mL vials) administered as an intravenous infusion.

If your flare persists, an additional 900 mg dose may be administered 1 week after the initial dose.

#### **Overdose:**

If you think you, or a person you are caring for, have taken too much **Spevigo**, contact a healthcare professional, hospital emergency department, or regional poison control centre immediately, even if there are no symptoms.

#### **What are possible side effects from using Spevigo?**

These are not all the possible side effects you may have when taking **Spevigo**. If you experience any side effects not listed here, tell your healthcare professional.

- urinary tract infections;
- upper respiratory tract infections;

- itching;
- feeling tired;
- redness, swelling, hardening, warmth, or pain at the injection site.

<b>Serious side effects and what to do about them</b>			
<b>Symptom / effect</b>	<b>Talk to your healthcare professional</b>		<b>Stop taking drug and get immediate medical help</b>
	<b>Only if severe</b>	<b>In all cases</b>	
<b>COMMON</b>			
<b>Urinary tract infections:</b> burning when you urinate, urinating more often than normal		✓	
<b>Upper respiratory tract infections:</b> fevers, chills or sweats, cough, shortness of breath		✓	
<b>Allergic (hypersensitivity) reactions and infusion reactions:</b> feeling faint, swelling of your face, eyelids, lips, mouth, tongue or throat, chest tightness, skin rash		✓	
<b>Serious allergic reactions that may occur days to weeks after receiving Spevigo:</b> skin rash that is different than the rash from GPP, fever, swollen lymph nodes, facial swelling, mouth sores		✓	

If you have a troublesome symptom or side effect that is not listed here or becomes bad enough to interfere with your daily activities, tell your healthcare professional.

## Reporting Side Effects

You can report any suspected side effects associated with the use of health products to Health Canada by:

- Visiting the Web page on Adverse Reaction Reporting (<https://www.canada.ca/en/health-canada/services/drugs-health-products/medeffect-canada.html>) for information on how to report online, by mail or by fax; or
- Calling toll-free at 1-866-234-2345.

*NOTE: Contact your health professional if you need information about how to manage your side effects. The Canada Vigilance Program does not provide medical advice.*

## Storage:

- Store **Spevigo** in a refrigerator at 2°C to 8°C.
- Do not freeze **Spevigo**. Do not use **Spevigo** if frozen, even if it has been thawed.
- Store **Spevigo** in original carton until it is to be used to protect from light.
- If needed, **Spevigo** prefilled syringes can be stored at room temperature up to 25°C for up to 14 days.
- Throw away **Spevigo** prefilled syringes if kept at room temperature for more than 14 days.

Keep **Spevigo** out of reach and sight of children.

## If you want more information about Spevigo:

- Talk to your healthcare professional.
- Find the full product monograph that is prepared for healthcare professionals and includes this Patient Medication Information by visiting the Health Canada website: (<https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/drug-product-database.html>); the manufacturer's website ([www.boehringer-ingenelheim.ca](http://www.boehringer-ingenelheim.ca)), or by calling 1-800-263-5103, extension 84633.

This leaflet was prepared by Boehringer Ingelheim (Canada) Ltd.

The information in this leaflet is current up to the time of the last revision date shown below, but more current information may be available from the manufacturer.

Last Revised:

## INSTRUCTIONS FOR USE

### SPEVIGO

#### (spesolimab injection)

#### Spevigo injection for subcutaneous use

These “Instructions for Use” contain information on how to inject Spevigo when the prescribed dose for you or your child requires 2 pre-filled syringes of Spevigo.

Read these Instructions for Use before you use Spevigo for the first time and each time you get a refill. There may be new information.

This information does not take the place of talking to your healthcare professional about your or your child’s medical condition or treatment. Your healthcare professional should show you the right way to inject Spevigo before you try to inject yourself or your child for the first time.

Your healthcare professional has prescribed a dose of Spevigo for you or your child that requires two injections to deliver a complete dose. **You must inject the contents of both Spevigo pre-filled syringes that come in the carton to deliver the complete dose.**


Spevigo is for one-time use. **Do not** re-use the pre-filled syringe.



#### Getting to know Spevigo

Spevigo comes in a pre-filled syringe with a safety cover. The needle is pulled back into the safety cover after injection.

**Figure 1: Spevigo before use and after use with the activated safety cover.**








**Important information you need to know before injecting Spevigo**



- **You must inject the contents of both Spevigo pre-filled syringes to deliver a complete dose.**
- Inspect the carton that the product comes in to be sure that you have the correct medicine, the correct number of pre-filled syringes for your or your child’s prescribed dose, for any damage, and the expiration date.
- **Do not** use Spevigo if the liquid is cloudy or contains flakes or large particles.
- **Do not** use Spevigo if the **expiration date (EXP)** has passed.
- **Do not** use Spevigo if the pre-filled syringe has been dropped.
- **Do not** remove the cap until you are ready to inject.
- Inject Spevigo under the skin (subcutaneous injection) in either the upper thighs or stomach-area (abdomen). **Do not** inject Spevigo into any other area of the body.
- **Keep Spevigo and all medicines out of the reach and sight of children.**









Follow the steps below when you use Spevigo:


<p><b>STEP 1</b></p>  <p>2 Spevigo pre-filled syringes</p> <p>2 cotton balls or gauze (not included)</p> <p>2 alcohol wipes (not included)</p> <p>1 sharps disposal container (not included)</p>	<p><b>Gathering supplies</b></p> <ul style="list-style-type: none"> <li>• Take the Spevigo carton out of the refrigerator and remove the pre-filled syringes from the carton.</li> <li>• Gather supplies listed and place them on a clean, flat work surface in a well-lit area.</li> <li>• If you do not have all the supplies listed, contact your pharmacist.</li> <li>• For disposal, see step 10: <b>“Disposing of the used Spevigo pre-filled syringes and caps.”</b></li> </ul>
<p><b>STEP 2</b></p> <div style="display: flex; justify-content: space-between;"> <div data-bbox="203 997 430 1291"> <p>Bring medicine to room temperature</p>  </div> <div data-bbox="438 997 641 1291"> <p>Wash hands</p>  </div> </div>	<p><b>Preparing to inject Spevigo</b></p> <ul style="list-style-type: none"> <li>• Wait 15 to 30 minutes to allow the medicine to reach room temperature to avoid discomfort during injection. <b>Do not</b> speed up the warming process in any way, such as using the microwave or placing the syringe in warm water.</li> <li>• <b>Do not</b> leave the pre-filled syringes in direct sunlight.</li> <li>• Wash your hands well with soap and water and dry them.</li> </ul>

<p><b>STEP 3</b></p>	<p><b>Inspecting the pre-filled syringes</b></p>
 <p>Check both pre-filled syringes now</p> <p>EXP MM YYYY</p> <p>medicine</p>	<p><b>Check both pre-filled syringes now:</b></p> <ul style="list-style-type: none"> <li>• Check to make sure the medicine name and dose on the pre-filled syringes match your or your child’s prescribed dose.</li> <li>• Check the expiration date on both pre-filled syringes. <b>Do not</b> use if the expiration date (EXP) has passed.</li> <li>• Check both pre-filled syringes for damage, cracks, and leakage. <b>Do not</b> use if any part of the pre-filled syringes appears cracked, broken, or is leaking.</li> <li>• Make sure the medicine in both pre-filled syringes is colourless to slightly yellow. It may contain tiny white or clear particles. <b>Do not</b> use if the medicine is cloudy or has flakes or large particles in it.</li> <li>• It is normal to see air bubbles, they do not need to be removed.</li> <li>• <b>Do not</b> use if the Spevigo pre-filled syringes have been dropped.</li> </ul>
<p><b>Preparing for your first injection</b></p>	
 <p>1</p> <p>2</p>	<p><b>Prepare for the first of two injections.</b></p> <p><b>Remember, you will repeat the following steps with the second pre-filled syringe right away after your first injection. Two injections are needed for a complete dose.</b></p>

<p><b>STEP 4</b></p>	<p><b>Choosing the injection site</b></p>
	<p>Choose an injection site.</p> <ul style="list-style-type: none"> <li>• You may use an area on your: <ul style="list-style-type: none"> <li>○ <b>upper thighs</b> or</li> <li>○ <b>stomach area (abdomen)</b>, except for an area 5 cm around your navel (belly button).</li> </ul> </li> <li>• Choose a <b>different injection site</b> each time you inject, at least 2 cm away from the last injection site.</li> <li>• <b>Do not</b> inject into an area near your waistline or belly button.</li> <li>• <b>Do not</b> inject into areas that are tender, bruised, red, hard, or scarred.</li> <li>• <b>Do not</b> inject through clothes.</li> </ul>
<p><b>STEP 5</b></p>	<p><b>Cleaning the injection site</b></p>
	<ul style="list-style-type: none"> <li>• Clean the injection site with an alcohol wipe and let air dry.</li> <li>• <b>Do not</b> touch this area again before injecting.</li> <li>• <b>Do not</b> fan or blow on the clean area.</li> </ul>

<p><b>STEP 6</b></p>	<p><b>Removing the cap</b></p>
	<ul style="list-style-type: none"> <li>• Hold the pre-filled syringe by the finger grip with one hand. With the other hand, pull the cap straight off. <ul style="list-style-type: none"> <li>○ <b>Do not</b> pull on or hold the plunger rod.</li> <li>○ <b>Do not</b> twist the cap. Twisting the cap could damage the needle.</li> <li>○ <b>Do not</b> use the prefilled syringe if the needle is bent or damaged. If you accidentally bend the needle <b>do not</b> attempt to straighten it.</li> </ul> </li> <li>• Put the cap aside.</li> <li>• Use right away after removing the cap. <ul style="list-style-type: none"> <li>○ <b>Do not</b> try to recap the needle. Re-capping can lead to needle-stick injury.</li> <li>○ <b>Do not</b> touch the needle or let the needle touch anything before injecting.</li> </ul> </li> </ul>
<p><b>STEP 7</b></p>	<p><b>Pinch the skin</b></p>
	<ul style="list-style-type: none"> <li>• Gently pinch the area of cleaned skin around your injection site and hold it firmly.</li> <li>• Keep the skin pinched during the entire injection. You will inject into the pinched skin.</li> <li>• <b>Do not</b> let go until you have removed the needle from your skin at the end of the injection.</li> </ul>
<p><b>STEP 8</b></p>	<p><b>Before injecting, review steps A, B, and C to learn the correct way to inject</b></p>
<p><b>Important: Do Not move the pre-filled syringe when inserting the needle into your skin, while injecting, or when removing the needle from your skin.</b></p>	
	<ul style="list-style-type: none"> <li>• Hold the pre-filled syringe by the blue finger grip. Avoid touching the blue thumb pad.</li> <li>• Using a quick, “dart-like” motion, insert the needle into the pinched skin at about a <b>45-degree angle</b>.</li> <li>• <b>Do not</b> move the needle while inserting or during the injection.</li> </ul>

<p><b>A Inserting the needle</b></p>	
 <p>Push firmly</p>	<p><b>To inject Spevigo:</b></p> <ul style="list-style-type: none"> <li>• Use your thumb to slowly press down on the blue thumb pad to push the plunger rod down inside the syringe body.</li> <li>• Continue pressing on the blue thumb pad until the plunger rod has moved all the way down.</li> <li>• Make sure that the blue thumb pad cannot be pressed any further so that the <b>built-in safety cover can be activated.</b></li> </ul>
<p><b>B Injecting the medicine</b></p>	
 <p>Remove thumb to activate the safety cover</p>	<ul style="list-style-type: none"> <li>• <b>Slowly remove your thumb</b> from the blue thumb pad, to move the needle out of your skin and up into the safety cover. <ul style="list-style-type: none"> <li>○ Check that the thumb pad springs back and that the needle is inside the safety cover.</li> <li>○ If the needle is not inside the safety cover call your healthcare professional. You may not have received a full dose.</li> </ul> </li> <li>• If there is bleeding, press a cotton ball or gauze on the site for a few seconds.</li> <li>• <b>Do not</b> rub the injection site.</li> <li>• Apply an adhesive bandage if needed.</li> </ul>
<p><b>C Checking injection is complete</b></p>	
<p><b>STEP 9</b></p>	<p><b>Second injection</b></p>
	<ul style="list-style-type: none"> <li>• <b>Choose a different injection site.</b> The new injection site should be at least 2 cm away from last injection site.</li> <li>• <b>Take the second pre-filled syringe.</b></li> <li>• <b>Repeat steps 4 through 8 right away.</b></li> <li>• Then continue to step 10.</li> </ul> <p><b>Important: You must inject the contents of both Spevigo pre-filled syringes to give a complete dose.</b></p>

<b>STEP 10</b>	<b>Disposing of the used Spevigo pre-filled syringes and caps</b>
	<ul style="list-style-type: none"><li>• Put the used syringes and caps in a special disposal container right away after use.</li><li>• <b>Do not</b> throw away (dispose of) the pre-filled syringes in the household waste.</li><li>• Your doctor, pharmacist, or nurse will tell you how to return the full sharps disposal container.</li><li>• <b>Do not</b> reuse the pre-filled syringes.</li></ul> <p><b>Important: Always keep the sharps disposal container out of the reach of children.</b></p>

Need help?

Call your doctor to talk about any questions you may have. For questions or concerns visit the manufacturer's website ([www.boehringer-ingelheim.ca](http://www.boehringer-ingelheim.ca)) or call 1-800-263-5103, extension 84633.